Top

Published in:

Open Access 01-10-2019 | Review Article

Long QT Syndrome: Genetics and Future Perspective

Authors: Eimear Wallace, Linda Howard, Min Liu, Timothy O’Brien, Deirdre Ward, Sanbing Shen, Terence Prendiville

Published in: Pediatric Cardiology | Issue 7/2019

Abstract

Long QT syndrome (LQTS) is an inherited primary arrhythmia syndrome that may present with malignant arrhythmia and, rarely, risk of sudden death. The clinical symptoms include palpitations, syncope, and anoxic seizures secondary to ventricular arrhythmia, classically torsade de pointes. This predisposition to malignant arrhythmia is from a cardiac ion channelopathy that results in delayed repolarization of the cardiomyocyte action potential. The QT interval on the surface electrocardiogram is a summation of the individual cellular ventricular action potential durations, and hence is a surrogate marker of the abnormal cellular membrane repolarization. Severely affected phenotypes administered current standard of care therapies may not be fully protected from the occurrence of cardiac arrhythmias. There are 17 different subtypes of LQTS associated with monogenic mutations of 15 autosomal dominant genes. It is now possible to model the various LQTS phenotypes through the generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes. RNA interference can silence or suppress the expression of mutant genes. Thus, RNA interference can be a potential therapeutic intervention that may be employed in LQTS to knock out mutant mRNAs which code for the defective proteins. CRISPR/Cas9 is a genome editing technology that offers great potential in elucidating gene function and a potential therapeutic strategy for monogenic disease. Further studies are required to determine whether CRISPR/Cas9 can be employed as an efficacious and safe rescue of the LQTS phenotype. Current progress has raised opportunities to generate in vitro human cardiomyocyte models for drug screening and to explore gene therapy through genome editing.

Schwartz PJ, Stramba-Badiale M, Crotti L, Pedrazzini M, Besana A, Bosi G, Gabbarini F, Goulene K, Insolia R, Mannarino S, Mosca F, Nespoli L, Rimini A, Rosati E, Salice P, Spazzolini C (2009) Prevalence of the congenital long-QT syndrome. Circulation 120(18):1761–1767. https://doi.org/10.1161/CIRCULATIONAHA.109.863209 CrossRefPubMedPubMedCentral

Schwartz PJ, Ackerman MJ, George AL Jr, Wilde AAM (2013) Impact of genetics on the clinical management of channelopathies. J Am Coll Cardiol 62(3):169–180. https://doi.org/10.1016/j.jacc.2013.04.044 CrossRefPubMedPubMedCentral

Weiss JN, Garfinkel A, Karagueuzian HS, Chen PS, Qu Z (2010) Early afterdepolarizations and cardiac arrhythmias. Heart Rhythm 7(12):1891–1899. https://doi.org/10.1016/j.hrthm.2010.09.017 CrossRefPubMedPubMedCentral

Schwartz PJ (1985) Idiopathic long QT syndrome: progress and questions. Am Heart J 109(2):399–411CrossRefPubMed

Rohatgi RK, Sugrue A, Bos JM, Cannon BC, Asirvatham SJ, Moir C, Owen HJ, Bos KM, Kruisselbrink T, Ackerman MJ (2017) Contemporary outcomes in patients with long QT syndrome. J Am Coll Cardiol 70(4):453–462. https://doi.org/10.1016/j.jacc.2017.05.046 CrossRefPubMed

Mizusawa Y, Horie M, Wilde AA (2014) Genetic and clinical advances in congenital long QT syndrome. Circ J 78(12):2827–2833CrossRefPubMed

Schwartz PJ, Crotti L, Insolia R (2012) Long-QT syndrome: from genetics to management. Circ Arrhythm Electrophysiol 5(4):868–877. https://doi.org/10.1161/CIRCEP.111.962019 CrossRefPubMedPubMedCentral

Chen L, Sampson KJ, Kass RS (2016) Cardiac delayed rectifier potassium channels in health and disease. Cardiac Electrophysiol Clin 8(2):307–322. https://doi.org/10.1016/j.ccep.2016.01.004 CrossRef

Modi S, Krahn AD (2011) Sudden cardiac arrest without overt heart disease. Circulation 123(25):2994–3008. https://doi.org/10.1161/CIRCULATIONAHA.110.981381 CrossRefPubMed

10.

Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, Vicentini A, Spazzolini C, Nastoli J, Bottelli G, Folli R, Cappelletti D (2003) Risk stratification in the long-QT syndrome. N Engl J Med 348(19):1866–1874. https://doi.org/10.1056/NEJMoa022147 CrossRefPubMed

11.

Priori SG, Napolitano C, Schwartz PJ, Grillo M, Bloise R, Ronchetti E, Moncalvo C, Tulipani C, Veia A, Bottelli G, Nastoli J (2004) Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 292(11):1341–1344. https://doi.org/10.1001/jama.292.11.1341 CrossRefPubMed

12.

Huang H, Kuenze G, Smith JA, Taylor KC, Duran AM, Hadziselimovic A, Meiler J, Vanoye CG, George AL Jr, Sanders CR (2018) Mechanisms of KCNQ1 channel dysfunction in long QT syndrome involving voltage sensor domain mutations. Sci Adv 4(3):aar2631. https://doi.org/10.1126/sciadv.aar2631 CrossRef

13.

Barsheshet A, Goldenberg I, O-Uchi J, Moss AJ, Jons C, Shimizu W, Wilde AA, McNitt S, Peterson DR, Zareba W, Robinson JL, Ackerman MJ, Cypress M, Gray DA, Hofman N, Kanters JK, Kaufman ES, Platonov PG, Qi M, Towbin JA, Vincent GM, Lopes CM, (2012) Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to beta-blocker therapy in type 1 long-QT syndrome. Circulation 125(16):1988–1996. https://doi.org/10.1161/CIRCULATIONAHA.111.048041 CrossRefPubMedPubMedCentral

14.

Waddell-Smith KE, Earle N, Skinner JR (2015) Must every child with long QT syndrome take a beta blocker? Arch Dis Child 100(3):279–282. https://doi.org/10.1136/archdischild-2014-306864 CrossRefPubMed

15.

Mehta A, Sequiera GL, Ramachandra CJ, Sudibyo Y, Chung Y, Sheng J, Wong KY, Tan TH, Wong P, Liew R, Shim W (2014) Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes. Cardiovasc Res 102(3):497–506. https://doi.org/10.1093/cvr/cvu060 CrossRefPubMed

16.

Seth R, Moss AJ, McNitt S, Zareba W, Andrews ML, Qi M, Robinson JL, Goldenberg I, Ackerman MJ, Benhorin J, Kaufman ES, Locati EH, Napolitano C, Priori SG, Schwartz PJ, Towbin JA, Vincent GM, Zhang L (2007) Long QT syndrome and pregnancy. J Am Coll Cardiol 49(10):1092–1098. https://doi.org/10.1016/j.jacc.2006.09.054 CrossRefPubMed

17.

Fatima A, Kaifeng S, Dittmann S, Xu G, Gupta MK, Linke M, Zechner U, Nguemo F, Milting H, Farr M, Hescheler J, Saric T (2013) The disease-specific phenotype in cardiomyocytes derived from induced pluripotent stem cells of two long QT syndrome type 3 patients. PLoS ONE 8(12):e83005. https://doi.org/10.1371/journal.pone.0083005 CrossRefPubMedPubMedCentral

18.

Ma D, Wei H, Zhao Y, Lu J, Li G, Sahib NB, Tan TH, Wong KY, Shim W, Wong P, Cook SA, Liew R (2013) Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells. Int J Cardiol 168(6):5277–5286. https://doi.org/10.1016/j.ijcard.2013.08.015 CrossRefPubMed

19.

Davis RP, Casini S, van den Berg CW, Hoekstra M, Remme CA, Dambrot C, Salvatori D, Oostwaard DW, Wilde AA, Bezzina CR, Verkerk AO, Freund C, Mummery CL (2012) Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation 125(25):3079–3091. https://doi.org/10.1161/CIRCULATIONAHA.111.066092 CrossRefPubMed

20.

Abriel H (2010) Cardiac sodium channel Na(v)1.5 and interacting proteins: physiology and pathophysiology. J Mol Cell Cardiol 48(1):2–11. https://doi.org/10.1016/j.yjmcc.2009.08.025 CrossRefPubMed

21.

Malan D, Zhang M, Stallmeyer B, Muller J, Fleischmann BK, Schulze-Bahr E, Sasse P, Greber B (2016) Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction. Basic Res Cardiol 111(2):14. https://doi.org/10.1007/s00395-016-0530-0 CrossRefPubMedPubMedCentral

22.

Zhang M, D'Aniello C, Verkerk AO, Wrobel E, Frank S, Ward-van Oostwaard D, Piccini I, Freund C, Rao J, Seebohm G, Atsma DE, Schulze-Bahr E, Mummery CL, Greber B, Bellin M (2014) Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and Lange-Nielsen syndrome: disease mechanisms and pharmacological rescue. Proc Natl Acad Sci USA 111(50):E5383–5392. https://doi.org/10.1073/pnas.1419553111 CrossRefPubMed

23.

Veerapandiyan A, Statland JM, Tawil R (1993) Andersen-Tawil syndrome. In: Adam MP, Ardinger HH, Pagon RA et al. (eds) GeneReviews^®. University of Washington, Seattle

24.

Mazzanti A, Maragna R, Vacanti G, Monteforte N, Bloise R, Marino M, Braghieri L, Gambelli P, Memmi M, Pagan E, Morini M, Malovini A, Ortiz M, Sacilotto L, Bellazzi R, Monserrat L, Napolitano C, Bagnardi V, Priori SG (2018) Interplay between genetic substrate, QTc duration, and arrhythmia risk in patients with long QT syndrome. J Am Coll Cardiol 71(15):1663–1671. https://doi.org/10.1016/j.jacc.2018.01.078 CrossRefPubMed

25.

Taggart NW, Haglund CM, Tester DJ, Ackerman MJ (2007) Diagnostic miscues in congenital long-QT syndrome. Circulation 115(20):2613–2620. https://doi.org/10.1161/CIRCULATIONAHA.106.661082 CrossRefPubMed

26.

Sy RW, van der Werf C, Chattha IS, Chockalingam P, Adler A, Healey JS, Perrin M, Gollob MH, Skanes AC, Yee R, Gula LJ, Leong-Sit P, Viskin S, Klein GJ, Wilde AA, Krahn AD (2011) Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands. Circulation 124(20):2187–2194. https://doi.org/10.1161/CIRCULATIONAHA.111.028258 CrossRefPubMed

27.

Page A, Aktas MK, Soyata T, Zareba W, Couderc JP (2016) "QT clock" to improve detection of QT prolongation in long QT syndrome patients. Heart Rhythm 13(1):190–198. https://doi.org/10.1016/j.hrthm.2015.08.037 CrossRefPubMed

28.

Abu-Zeitone A, Peterson DR, Polonsky B, McNitt S, Moss AJ (2014) Efficacy of different beta-blockers in the treatment of long QT syndrome. J Am Coll Cardiol 64(13):1352–1358. https://doi.org/10.1016/j.jacc.2014.05.068 CrossRefPubMed

29.

Etheridge SP, Compton SJ, Tristani-Firouzi M, Mason JW (2003) A new oral therapy for long QT syndrome: long-term oral potassium improves repolarization in patients with HERG mutations. J Am Coll Cardiol 42(10):1777–1782CrossRefPubMed

30.

Mehta A, Ramachandra CJA, Singh P, Chitre A, Lua CH, Mura M, Crotti L, Wong P, Schwartz PJ, Gnecchi M, Shim W (2018) Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model. Eur Heart J 39(16):1446–1455. https://doi.org/10.1093/eurheartj/ehx394 CrossRefPubMed

31.

Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AA, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P, Bloise R (2001) Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 103(1):89–95CrossRefPubMed

32.

Mohler PJ, Schott JJ, Gramolini AO, Dilly KW, Guatimosim S, duBell WH, Song LS, Haurogne K, Kyndt F, Ali ME, Rogers TB, Lederer WJ, Escande D, Le Marec H, Bennett V (2003) Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 421(6923):634–639. https://doi.org/10.1038/nature01335 CrossRefPubMed

33.

Shimizu W (2005) The long QT syndrome: therapeutic implications of a genetic diagnosis. Cardiovasc Res 67(3):347–356. https://doi.org/10.1016/j.cardiores.2005.03.020 CrossRefPubMed

34.

Miyamoto K, Aiba T, Kimura H, Hayashi H, Ohno S, Yasuoka C, Tanioka Y, Tsuchiya T, Yoshida Y, Tsuboi I, Nakajima I, Ishibashi K, Okamura H, Noda T, Ishihara M, Anzai T, Yasuda S, Miyamoto Y, Kamakura S, Kusano K, Ogawa H, Horie M, Shimizu W (2015) Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations. Heart Rhythm 12(3):596–603. https://doi.org/10.1016/j.hrthm.2014.12.009 CrossRefPubMed

35.

Sansone V, Tawil R (2007) Management and treatment of Andersen-Tawil syndrome (ATS). Neurotherapeutics 4(2):233–237. https://doi.org/10.1016/j.nurt.2007.01.005 CrossRefPubMed

36.

Dufendach KA, Timothy K, Ackerman MJ, Blevins B, Pflaumer A, Etheridge S, Perry J, Blom NA, Temple J, Chowdhury D, Skinner JR, Johnsrude C, Bratincsak A, Bos JM, Shah M (2018) Clinical outcomes and modes of death in timothy syndrome: a multicenter international study of a rare disorder. JACC Clin Electrophysiol 4(4):459–466. https://doi.org/10.1016/j.jacep.2017.08.007 CrossRefPubMed

37.

Patel C, Antzelevitch C (2008) Pharmacological approach to the treatment of long and short QT syndromes. Pharmacol Ther 118(1):138–151. https://doi.org/10.1016/j.pharmthera.2008.02.001 CrossRefPubMedPubMedCentral

38.

Schwartz PJ, Priori SG, Cerrone M, Spazzolini C, Odero A, Napolitano C, Bloise R, De Ferrari GM, Klersy C, Moss AJ, Zareba W, Robinson JL, Hall WJ, Brink PA, Toivonen L, Epstein AE, Li C, Hu D (2004) Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation 109(15):1826–1833. https://doi.org/10.1161/01.CIR.0000125523.14403.1E CrossRefPubMed

39.

Ackerman MJ, Zipes DP, Kovacs RJ, Maron BJ (2015) Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 10: the cardiac channelopathies: a scientific statement from the American Heart Association and American College of Cardiology. J Am Coll Cardiol 66(21):2424–2428. https://doi.org/10.1016/j.jacc.2015.09.042 CrossRefPubMed

40.

Sallam K, Kodo K, Wu JC (2014) Modeling inherited cardiac disorders. Circ J 78(4):784–794CrossRefPubMedPubMedCentral

41.

Friedrichs S, Malan D, Sasse P (2013) Modeling long QT syndromes using induced pluripotent stem cells: current progress and future challenges. Trends Cardiovasc Med 23(4):91–98. https://doi.org/10.1016/j.tcm.2012.09.006 CrossRefPubMed

42.

Mummery CL, Zhang J, Ng ES, Elliott DA, Elefanty AG, Kamp TJ (2012) Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ Res 111(3):344–358. https://doi.org/10.1161/CIRCRESAHA.110.227512 CrossRefPubMedPubMedCentral

43.

Mauritz C, Schwanke K, Reppel M, Neef S, Katsirntaki K, Maier LS, Nguemo F, Menke S, Haustein M, Hescheler J, Hasenfuss G, Martin U (2008) Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation 118(5):507–517. https://doi.org/10.1161/CIRCULATIONAHA.108.778795 CrossRefPubMed

44.

Halbach M, Egert U, Hescheler J, Banach K (2003) Estimation of action potential changes from field potential recordings in multicellular mouse cardiac myocyte cultures. Cell Physiol Biochem 13(5):271–284. https://doi.org/10.1159/000074542 CrossRefPubMed

45.

Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L, Dorn T, Goedel A, Hohnke C, Hofmann F, Seyfarth M, Sinnecker D, Schomig A, Laugwitz KL (2010) Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 363(15):1397–1409. https://doi.org/10.1056/NEJMoa0908679 CrossRefPubMed

46.

Muller M, Seufferlein T, Illing A, Homann J (2013) Modelling human channelopathies using induced pluripotent stem cells: a comprehensive review. Stem Cells Int 2013:496501. https://doi.org/10.1155/2013/496501 CrossRefPubMedPubMedCentral

47.

Wei H, Wu J, Liu Z (2018) Studying KCNQ1 mutation and drug response in type 1 long QT syndrome using patient-specific induced pluripotent stem cell-derived cardiomyocytes. Methods Mol Biol 1684:7–28. https://doi.org/10.1007/978-1-4939-7362-0_2 CrossRefPubMed

48.

Mura M, Lee YK, Ginevrino M, Zappatore R, Pisano F, Boni M, Dagradi F, Crotti L, Valente EM, Schwartz PJ, Tse HF, Gnecchi M (2018) Generation of the human induced pluripotent stem cell (hiPSC) line PSMi002-A from a patient affected by the Jervell and Lange-Nielsen syndrome and carrier of two compound heterozygous mutations on the KCNQ1 gene. Stem Cell Res 29:157–161. https://doi.org/10.1016/j.scr.2018.04.002 CrossRefPubMed

49.

Ma D, Wei H, Lu J, Huang D, Liu Z, Loh LJ, Islam O, Liew R, Shim W, Cook SA (2015) Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes. Stem Cell Res Ther 6:39. https://doi.org/10.1186/s13287-015-0027-z CrossRefPubMedPubMedCentral

50.

Wuriyanghai Y, Makiyama T, Sasaki K, Kamakura T, Yamamoto Y, Hayano M, Harita T, Nishiuchi S, Chen J, Kohjitani H, Hirose S, Yokoi F, Gao J, Chonabayashi K, Watanabe K, Ohno S, Yoshida Y, Kimura T, Horie M (2018) Complex aberrant splicing in the induced pluripotent stem cell-derived cardiomyocytes from a patient with long QT syndrome carrying KCNQ1-A344Aspl mutation. Heart Rhythm 15(10):1566–1574. https://doi.org/10.1016/j.hrthm.2018.05.028 CrossRefPubMed

51.

Mura M, Ginevrino M, Zappatore R, Pisano F, Boni M, Castelletti S, Crotti L, Valente EM, Schwartz PJ, Gnecchi M (2018) Generation of the human induced pluripotent stem cell (hiPSC) line PSMi003-A from a patient affected by an autosomal recessive form of Long QT Syndrome type 1. Stem Cell Res 29:170–173. https://doi.org/10.1016/j.scr.2018.04.003 CrossRefPubMed

52.

Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, Feldman O, Gepstein A, Arbel G, Hammerman H, Boulos M, Gepstein L (2011) Modelling the long QT syndrome with induced pluripotent stem cells. Nature 471(7337):225–229. https://doi.org/10.1038/nature09747 CrossRefPubMed

53.

Matsa E, Rajamohan D, Dick E, Young L, Mellor I, Staniforth A, Denning C (2011) Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J 32(8):952–962. https://doi.org/10.1093/eurheartj/ehr073 CrossRefPubMedPubMedCentral

54.

Bellin M, Casini S, Davis RP, D'Aniello C, Haas J, Ward-van Oostwaard D, Tertoolen LG, Jung CB, Elliott DA, Welling A, Laugwitz KL, Moretti A, Mummery CL (2013) Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. EMBO J 32(24):3161–3175. https://doi.org/10.1038/emboj.2013.240 CrossRefPubMedPubMedCentral

55.

Lahti AL, Kujala VJ, Chapman H, Koivisto AP, Pekkanen-Mattila M, Kerkela E, Hyttinen J, Kontula K, Swan H, Conklin BR, Yamanaka S, Silvennoinen O, Aalto-Setala K (2012) Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech 5(2):220–230. https://doi.org/10.1242/dmm.008409 CrossRef

56.

Garg P, Oikonomopoulos A, Chen H, Li Y, Lam CK, Sallam K, Perez M, Lux RL, Sanguinetti MC, Wu JC (2018) Genome editing of induced pluripotent stem cells to decipher cardiac channelopathy variant. J Am Coll Cardiol 72(1):62–75. https://doi.org/10.1016/j.jacc.2018.04.041 CrossRefPubMedPubMedCentral

57.

Malan D, Friedrichs S, Fleischmann BK, Sasse P (2011) Cardiomyocytes obtained from induced pluripotent stem cells with long-QT syndrome 3 recapitulate typical disease-specific features in vitro. Circ Res 109(8):841–847. https://doi.org/10.1161/CIRCRESAHA.111.243139 CrossRefPubMed

58.

Veerman CC, Mengarelli I, Lodder EM, Kosmidis G, Bellin M, Zhang M, Dittmann S, Guan K, Wilde AAM, Schulze-Bahr E, Greber B, Bezzina CR, Verkerk AO (2017) Switch from fetal to adult SCN5A isoform in human induced pluripotent stem cell-derived cardiomyocytes unmasks the cellular phenotype of a conduction disease-causing mutation. J Am Heart Assoc 6:7. https://doi.org/10.1161/JAHA.116.005135 CrossRef

59.

Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F (2013) Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8(11):2281–2308. https://doi.org/10.1038/nprot.2013.143 CrossRefPubMedPubMedCentral

60.

Shabbir MA, Hao H, Shabbir MZ, Hussain HI, Iqbal Z, Ahmed S, Sattar A, Iqbal M, Li J, Yuan Z (2016) Survival and evolution of CRISPR-Cas system in prokaryotes and its applications. Front Immunol 7:375. https://doi.org/10.3389/fimmu.2016.00375 CrossRefPubMedPubMedCentral

61.

Zaboikin M, Zaboikina T, Freter C, Srinivasakumar N (2017) Non-homologous end joining and homology directed DNA repair frequency of double-stranded breaks introduced by genome editing reagents. PLoS ONE 12(1):e0169931. https://doi.org/10.1371/journal.pone.0169931 CrossRefPubMedPubMedCentral

62.

Johansen AK, Molenaar B, Versteeg D, Leitoguinho AR, Demkes C, Spanjaard B, de Ruiter H, Akbari Moqadam F, Kooijman L, Zentilin L, Giacca M, van Rooij E (2017) Postnatal cardiac gene editing using CRISPR/Cas9 with AAV9-mediated delivery of short guide RNAs results in mosaic gene disruption. Circ Res 121(10):1168–1181. https://doi.org/10.1161/CIRCRESAHA.116.310370 CrossRefPubMed

63.

Chew WL (2018) Immunity to CRISPR Cas9 and Cas12a therapeutics. Wiley Interdiscip Rev Syst Biol Med 10(1):e1408. https://doi.org/10.1002/wsbm.1408 CrossRef

64.

Lu X, Yang X, Huang X, Huang C, Sun HH, Jin L, Xu W, Mao H, Guo J, Zhou J, Lian J (2013) RNA interference targeting E637K mutation rescues hERG channel currents and restores its kinetic properties. Heart Rhythm 10(1):128–136. https://doi.org/10.1016/j.hrthm.2012.09.124 CrossRefPubMed

65.

Li G, Ma S, Sun C (2015) RNA interference-based therapeutics for inherited long QT syndrome. Exp Ther Med 10(2):395–400. https://doi.org/10.3892/etm.2015.2573 CrossRefPubMedPubMedCentral

66.

Matsa E, Dixon JE, Medway C, Georgiou O, Patel MJ, Morgan K, Kemp PJ, Staniforth A, Mellor I, Denning C (2014) Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes. Eur Heart J 35(16):1078–1087. https://doi.org/10.1093/eurheartj/eht067 CrossRefPubMed

67.

Mazzanti A, Maragna R, Faragli A, Monteforte N, Bloise R, Memmi M, Novelli V, Baiardi P, Bagnardi V, Etheridge SP, Napolitano C, Priori SG (2016) Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3. J Am Coll Cardiol 67(9):1053–1058. https://doi.org/10.1016/j.jacc.2015.12.033 CrossRefPubMedPubMedCentral

68.

Li G, Cheng G, Wu J, Ma S, Sun C (2014) New iPSC for old long QT syndrome modeling: putting the evidence into perspective. Exp Biol Med (Maywood) 239:131–140. https://doi.org/10.1177/1535370213514000 CrossRef

Title: Long QT Syndrome: Genetics and Future Perspective
Authors: Eimear Wallace
Linda Howard
Min Liu
Timothy O’Brien
Deirdre Ward
Sanbing Shen
Terence Prendiville
Publication date: 01-10-2019
Publisher: Springer US
Published in: Pediatric Cardiology / Issue 7/2019
Print ISSN: 0172-0643
Electronic ISSN: 1432-1971
DOI: https://doi.org/10.1007/s00246-019-02151-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The STEP trials

Springer Medicine

Long QT Syndrome: Genetics and Future Perspective

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2019

Propofol Formulation Affects Myocardial Function in Newborn Infants

Decrease in Cerebral Oxygen Saturation During the 6-Minute Walk Test in Pediatric Pulmonary Arterial Hypertension

Use of Near-Infrared Spectroscopy to Monitor Lower Extremity Perfusion in Pediatric Patients Undergoing Cardiac Catheterization

Phases and Mechanisms of Embryonic Cardiomyocyte Proliferation and Ventricular Wall Morphogenesis

Postnatal Outcome Following Prenatal Diagnosis of Discordant Atrioventricular and Ventriculoarterial Connections

Tbx3-Mediated Regulation of Cardiac Conduction System Development and Function: Potential Contributions of Alternative RNA Processing

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page